Die 89bio-Aktie (ISIN US28252C1099) steht nach der jüngsten Unternehmensübernahme im Fokus, denn für jede ETNB-Aktie wurde ein fester Barbetrag von 14,50 US-Dollar sowie eine zusätzliche Aktie des neuen Unternehmens gewährt, wie aus einem Corporate-Action-Hinweis per 28.08.2026 hervorgeht. Übernahmebedingungen und Bewertungsniveau Laut einem aktuellen Corporate-Action-Tracker erhalten frühere Anteilseigner von 89bio je gehaltene ETNB-Aktie 14,50 US-Dollar in bar und eine neue Aktie der Nachfolgegesellschaft; dieser Paketpreis bildet de facto den Bewertungsanker für die 89bio-Aktie am 28.08.2026.

Newleos Therapeutics, a clinical-stage biotech focused on neuropsychiatric disorders, appointed Rohan Palekar to its Board of Directors and elected him Chairman. Christoph Westphal, who has served as Executive Chairman since Newleos’ founding, will step down from that role but remain on the Board representing founding investor Longwood Fund.According to Newleos, Palekar brings over 30 years of biotechnology and pharmaceutical experience, including serving as founding CEO of 89bio, where he led multiple programs from preclinical through Phase 3 in liver and cardiometabolic diseases; 89bio was acquired by Roche in 2025 for up to $3.5 billion. He previously was President and CEO of Avanir Pharmaceuticals, which was acquired by Otsuka Pharmaceutical in 2015, and Chief Commercial Officer at Medivation, after senior roles at Johnson & Johnson. Newleos highlights his CNS and company-building background as it approaches key clinical inflection points in ongoing anxiety trials. Palekar also serves on the board of Neurogene (Nasdaq: NGNE) and previously served on Neoleukin Therapeutics’ board.

89bio hat kürzlich Quartalszahlen vorgelegt, die Analysten überzeugen. Jefferies belässt das Rating auf Buy mit Kursziel. Die Biotech-Aktie zeigt Momentum im klinischen Entwicklungsfortschritt.

Investment banks and executives will reap over $150 million in fees from two major Bay Area biotech deals.

Shareholders to Receive $54 Per Share in Cash and CVR of $6 Per Share  Advances Akero’s Mission of Bringing Novel Therapies to Patients with High Unmet...

Halper Sadeh LLC is probing several companies, including 89bio and Tourmaline Bio, for potential breaches of federal securities laws affecting shareholders.

Roche acquired 89bio for $2.4B after multiple increased offers and no competing bids. Deal included exploring pegozafermin for MASH and followed 2 years of discussions.

Let's make a deal: How a Bay Area drug company landed a potential $3.5 billion deal with Genentech parent Roche

Roche acquired 89bio for $2.4B after multiple increased offers and no competing bids. Deal included exploring pegozafermin for MASH and followed 2 years of discussions.

Let's make a deal: How a Bay Area drug company landed a potential $3.5 billion deal with Genentech parent Roche

Halper Sadeh LLC is probing Premier, Metsera, and 89bio over potential securities law violations. Shareholders can explore their rights.

CVRs or similarly structured milestone payments are now a mainstay among both private and public takeovers.

CVRs or similarly structured milestone payments are now a mainstay among both private and public takeovers.